This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mednax's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Focusing on recent additions and future growth prospects for American Anesthesiology, three of our 10 acquisitions were in anesthesia, with two coming in the fourth quarter. In November, we added Austin Anesthesiology Group, the first Texas-based group to join American Anesthesiology. This group practice employed 66 physicians and 71 cRNA, practicing as part of an anesthesia care team model with annual anesthesia volumes that the practice exceeding 85000 cases. In December, we also announced the acquisition of Burlington Anesthesia Associates in Mount Holly, New Jersey, the first New Jersey practice to join American Anesthesiology. This practice consists of 17 anesthesiologists who practice as part of an anesthesia care team model that employs 25 cRNAs.

Both of these groups by joining MEDNAX are seeking the stability and resources that come with our national group model so that they can focus on doing what they do best taking care of their patients.

With the addition of Texas and New Jersey anesthesia practices, we are expanding beyond the Southeast to our national model as planned. Both of these states are solid geographies for us in our historical pediatric business and now they represent an expanded footprint and the advancement of the American Anesthesiology national model.

We plan to continue this path in 2012 as we expand into states in which we currently have pediatric business while at the same time moving into states which represent a new footprint for American Anesthesiology. Overall, we are not seeing anything that would suggest the level of acquisition activity we've experienced in the recent past will slowdown.

We're managing a very full pipeline that includes practices within our historical neonatal, maternal fetal medicine and pediatric cardiology practices. Additionally, we are confident that now is the time to take our foot off the brake a bit and that we have the team in place to further grow our anesthesia operations.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,941.08 -99.29 -0.55%
S&P 500 2,105.85 -5.88 -0.28%
NASDAQ 5,062.16 -20.7690 -0.41%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs